His primary areas of study are Biochemistry, Bile acid, Internal medicine, Endocrinology and Cholesterol 7 alpha-hydroxylase. His Bile acid study frequently links to other fields, such as Microbial metabolism. Phillip B. Hylemon combines subjects such as Probiotic and Feces with his study of Internal medicine.
Phillip B. Hylemon interconnects Nonalcoholic fatty liver disease, Steatohepatitis, Phosphorylation and Biliary tract in the investigation of issues within Endocrinology. His Cholesterol 7 alpha-hydroxylase research includes elements of Reverse cholesterol transport and Hepatocyte. His research integrates issues of Microbiology and Bacteria in his study of CYP8B1.
His scientific interests lie mostly in Biochemistry, Internal medicine, Bile acid, Endocrinology and Cholesterol. Biochemistry is closely attributed to Molecular biology in his research. His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology, Feces and Rifaximin.
His research investigates the connection with Bile acid and areas like Bacteria which intersect with concerns in Microbiology. His studies deal with areas such as Reductase and Hepatocyte as well as Cholesterol. His study focuses on the intersection of Cirrhosis and fields such as Gut flora with connections in the field of Microbiome.
The scientist’s investigation covers issues in Internal medicine, Cirrhosis, Gastroenterology, Bile acid and Endocrinology. His work carried out in the field of Cirrhosis brings together such families of science as Feces, Antibiotics, Cohort study and Dysbiosis. His Gastroenterology research includes themes of Gut flora, Rifaximin and Itching.
His Bile acid study is associated with Biochemistry. In his work, Bile acid metabolism, Carbon dioxide and Symbiosis is strongly intertwined with Acetogenesis, which is a subfield of Biochemistry. His Endocrinology research incorporates elements of Sulfation and Farnesoid X receptor.
His primary areas of investigation include Internal medicine, Bile acid, Cirrhosis, Liver injury and Gastroenterology. His work in Internal medicine tackles topics such as Endocrinology which are related to areas like Alkaline phosphatase, Nuclear receptor, Obeticholic acid, Triptolide and Farnesoid X receptor. To a larger extent, Phillip B. Hylemon studies Biochemistry with the aim of understanding Bile acid.
Phillip B. Hylemon interconnects Symbiosis and Acetogenesis in the investigation of issues within Biochemistry. His Cirrhosis research is multidisciplinary, incorporating elements of Steatosis, Antibiotics, Steatohepatitis, Type 2 diabetes and Dysbiosis. The various areas that Phillip B. Hylemon examines in his Liver injury study include Cancer research, Primary sclerosing cholangitis and Cholestasis.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Bile salt biotransformations by human intestinal bacteria.
Jason M. Ridlon;Dae Joong Kang;Phillip B. Hylemon.
Journal of Lipid Research (2006)
Bile Acids and the Gut Microbiome
Jason M. Ridlon;Dae Joong Kang;Phillip B. Hylemon;Jasmohan S. Bajaj.
Current Opinion in Gastroenterology (2014)
Altered profile of human gut microbiome is associated with cirrhosis and its complications
Jasmohan S. Bajaj;Douglas M. Heuman;Phillip B. Hylemon;Arun J. Sanyal.
Journal of Hepatology (2014)
Bile acids as regulatory molecules.
Phillip B. Hylemon;Huiping Zhou;William M. Pandak;Shunlin Ren.
Journal of Lipid Research (2009)
Modulation of the Fecal Bile Acid Profile by Gut Microbiota in Cirrhosis
Genta Kakiyama;William M. Pandak;Patrick M. Gillevet;Phillip B. Hylemon.
Journal of Hepatology (2013)
Consequences of bile salt biotransformations by intestinal bacteria
Jason M. Ridlon;Spencer C. Harris;Shiva Bhowmik;Dae Joong Kang.
Gut microbes (2016)
Linkage of gut microbiome with cognition in hepatic encephalopathy
Jasmohan Singh Bajaj;Jason M. Ridlon;Phillip B. Hylemon;Leroy R Thacker.
American Journal of Physiology-gastrointestinal and Liver Physiology (2012)
Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation
Jasmohan Singh Bajaj;Phillip B. Hylemon;Jason M. Ridlon;Douglas M. Heuman.
American Journal of Physiology-gastrointestinal and Liver Physiology (2012)
Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy.
Jasmohan S. Bajaj;Douglas M. Heuman;Arun J. Sanyal;Phillip B. Hylemon.
PLOS ONE (2013)
Down-regulation of Cholesterol 7α-Hydroxylase (CYP7A1) Gene Expression by Bile Acids in Primary Rat Hepatocytes Is Mediated by the c-Jun N-terminal Kinase Pathway
Seema Gupta;R. Todd Stravitz;Paul Dent;Phillip B. Hylemon.
Journal of Biological Chemistry (2001)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of Tsukuba
Virginia Commonwealth University
Virginia Commonwealth University
Virginia Commonwealth University
Virginia Commonwealth University
China Pharmaceutical University
Virginia Commonwealth University
Northeast Ohio Medical University
University of North Carolina at Chapel Hill
University of California, Davis
University of Alberta
University of Ljubljana
Osaka University
University of Copenhagen
University of Southampton
University of Florida
Queen Mary University of London
Izmir Biomedicine and Genome Center
Kagoshima University
University of Bordeaux
University of Bonn
University of Chicago
University of Oslo
Hospital Universitario La Paz
National Institute for Health Research
University of California, San Diego